Harmony Biosciences (HRMY) posts preliminary 2025 revenue, 2026 guidance and clinical update
Rhea-AI Filing Summary
Harmony Biosciences Holdings, Inc. filed a current report describing a new press release with preliminary, unaudited net product revenue for the fourth quarter and full year ended December 31, 2025. The release also includes the company’s guidance for 2026 net product revenue and an update on its clinical programs.
The company will present at the 44th Annual JP Morgan Healthcare Conference on January 13, 2026, and the related presentation is attached to the report. The materials, including the press release and slideshow, are being furnished rather than filed, and the company highlights that they contain forward-looking statements subject to risks and uncertainties described in its prior SEC reports.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction | (Commission | (IRS Employer |
of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Trading | | Name of each exchange | |
Title of each class | Symbol(s) | on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On January 12, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its preliminary unaudited net product revenue for the fourth quarter and year ended December 31, 2025. In addition, the Company provided guidance related to 2026 net product revenue and provided an update on clinical programs. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
The Company will also be presenting at the 44th Annual JP Morgan Healthcare Conference on January 13, 2026. The presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
This Current Report on Form 8-K and its contents (including Exhibits 99.1 and 99.2) are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Note Regarding Forward-Looking Statements
Certain statements in this Current Report on Form 8-K constitute “forward-looking statements” within the meaning of the federal securities laws. These statements are based on management’s current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results. These forward looking statements are only predictions, not historical fact, and involve certain risks and uncertainties, as well as assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. While the Company believes that its assumptions are reasonable, it is very difficult to predict the impact of known factors, and, of course, it is impossible to anticipate all factors that could affect actual results. There are many risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein including the risks discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission (“SEC,”) on February 25, 2025, as well as other factors described from time to time in the Company’s filings with the SEC. Such forward-looking statements are made only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to publicly update or revise any forward-looking statement because of new information, future events or otherwise, except as otherwise required by law. If it does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit | | |
No. | Description | |
99.1* | Press release issued by the Company, dated January 12, 2026. | |
99.2* | Harmony Biosciences Holdings, Inc. 44th Annual JP Morgan Healthcare Conference Presentation, January 13, 2026. | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
* | This Exhibit is furnished herewith and will not be deemed “filed” for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except to the extent that Harmony Biosciences Holdings, Inc. specifically incorporates it by reference. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HARMONY BIOSCIENCES HOLDINGS, INC. | ||
Date: January 12, 2026 | By: | /s/ Sandip Kapadia |
Sandip Kapadia | ||
Chief Financial Officer and Chief Administrative Officer | ||
FAQ
What did Harmony Biosciences (HRMY) disclose in this 8-K?
Harmony Biosciences reported that it issued a press release with preliminary unaudited net product revenue for the fourth quarter and full year ended December 31, 2025. It also shared 2026 net product revenue guidance and provided an update on its clinical programs, with the press release attached as Exhibit 99.1.
Does the Harmony Biosciences 8-K include 2026 revenue guidance?
Yes. The company states that the press release attached as Exhibit 99.1 includes guidance related to 2026 net product revenue. Specific numbers are contained in the exhibit rather than in the body of the report.
What period do the preliminary results from Harmony Biosciences (HRMY) cover?
The company’s press release provides preliminary unaudited net product revenue for the fourth quarter and year ended December 31, 2025. These figures are described as preliminary and unaudited.
What upcoming event did Harmony Biosciences announce in this report?
Harmony Biosciences disclosed that it will present at the 44th Annual JP Morgan Healthcare Conference on January 13, 2026. The associated presentation materials are attached as Exhibit 99.2.
Are the Harmony Biosciences exhibits considered filed or furnished?
The company specifies that the report and its contents, including Exhibits 99.1 and 99.2, are furnished and not deemed filed for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act, except where expressly incorporated by reference.
Does Harmony Biosciences include forward-looking statements in this disclosure?
Yes. The company notes that the materials contain forward-looking statements based on current expectations and subject to risks and uncertainties. It refers readers to the Risk Factors section of its Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings for a discussion of these risks.
Where can investors find more detail on Harmony Biosciences’ clinical programs?
The report indicates that additional detail is provided in the press release and the JP Morgan Healthcare Conference presentation, attached as Exhibits 99.1 and 99.2, which include an update on clinical programs.
